WH

Wende Hutton

General Partner at Canaan Partners

Menlo Park, California

VC
Investor

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $250,000.00

  • Max Investment:

    $20,000,000.00

  • Target Investment:

    $10,000,000.00

Education

Lists including Wende

AT
AS
AT
AH

All Series A Investors

14752 people

AM
AT
AS
AR

All Seed Investors

19695 people

Investments

Qlaris Bio

Series B

Total Funding: $24M

OncoResponse

Series A

Total Funding: $110M

Antiva Biosciences

Series B

Total Funding: $140M

MoCaFi

Series A

Total Funding: $40M

Hyalex Orthopaedics

Series A

Total Funding: $33M

Glooko

Series B

Total Funding: $73M

ReVision Optics

Series C

Total Funding: $180M

Chrono Therapeutics

Series A

Total Funding: $80M

Minimally invasive devices

Series B

Total Funding: $32M

ALDEA Pharmaceuticals

Debt Financing

Total Funding: $31M

Work Experience

Canaan Partners

2004

  • General Partner

    2004

    Investor in Med tech/Digital Health and Biopharmaceuticals. Recent boards include Labrys Biologics (acquired by Teva), Dermira (DERM), Transcend Medical (acquired by Alcon/Novartis) and Chimerix (CMRX). Current boards include Antiva Biosciences, Glooko, OncoResponse, Qlaris Bio and Hyalex Orthopeadics.

Keepyoursight

2013 - 2013

  • supporter

    2013 - 2013

Mayfield Fund

1993 - 2001

  • General Partner

    1993 - 2001

GenPharm International

1991 - 1992

  • General Manager, Transgenic Lab Products

    1991 - 1992

Nellcor

1986 - 1990

  • Director, International Business Unit; Dir of Business Development; Marketing

    1986 - 1990